Effects on Inflammation of Newly-Synthesized Hexapeptide with Affinity to Opioid and Nociceptin Receptors

详细信息    查看全文

• 作者：R. N. Zamfirova (1)
  P. I. Mateeva (1)
  N. D. Pavlov (2)
  E. D. Naydenova (2)
  
• 关键词：Inflammation ; Nociception/orphanin FQ ; Nociceptin receptor ; Hexapeptides ; Ac ; RYYRWK ; NH2 ; Indomethacin
• 刊名：International Journal of Peptide Research and Therapeutics
• 出版年：2014
• 出版时间：September 2014
• 年：2014
• 卷：20
• 期：3
• 页码：385-389
• 全文大小：397 KB
• 参考文献：1. Brookes Z, Stedman E, Guerrini R, Lawton B, Calo G, Lamber D (2007) Proinflammatory and vasodilatator effects of nociceptin/orphanin FQ in the rat mesenteric microcirculation are mediated by histamine. Am J Physiol 293:H2977–H2985. doi:10.1152/ajpheart.00448
  2. Calo G, Guerrini R, Rizzi A, Salvadori S, Regoli D (2000) Pharmacology of nociceptin and its receptor: a novel theraputic target. Br J Pharmacol 129:1261-283. doi:10.1038/sj.bjp.0703219 CrossRef
  3. Fiset ME, Gilbert C, Poubelle PE, Pouliot M (2003) Human neutrophils as a source of N/OFQ: a novel link between pain and inflammation. Biochemistry 42:10498-0505 CrossRef
  4. Guerrini R, Calò G, Rizzi A, Bigoni R, Rizzi D, Regoli D, Salvadori S (2000) Structure-activity relationships of nociceptin and related peptides: comparison with dynorphin A. Peptides 21(7):923-33 CrossRef
  5. Gyenge M, Hantos M, Laufer R, Tekes K (2006) Effect of nociception on histamine and serotonin release in central nervous system. Acta Pharm Hung 76(3):127-32
  6. Hantos MB, Szalay F, Lakatos PL, Hegedus D, Firneisz G, Reiczigel J, Torok T, Tekes K (2002) Elevated plasma nociception level in patients with Wilson disease. Brain Res Bull 58(3):331-33 CrossRef
  7. Helyes Z, Németh J, Pintér E, Szolesányi J (1997) Inhibition by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals. Br J Pharmacol 121:613-15
  8. Henderson G, McKnight AT (1997) The orphan opioid receptor and its endogenous ligand-nociceptin/orphanin FQ. Trends Pharmacol Sci 18(8):293-00 CrossRef
  9. Kimura T, Kitaichi K, Hiramatsu K, Yoshida M, Ito Y, Kume H, Yamaki K, Suzuki R, Takagi K (2000) Intradermal application of nociception increases vascular permeability in rats: the possible involvement of histamine release from mast cells. Eur J Pharmacol 407(3):327-32 CrossRef
  10. Kondo I, Marvizon JC, Song B, Salgado F, Codeluppi S, Hua XY, Yaksh TL (2005) Inhibition by spinal mu- and delta-opioid agonists of afferent-evoked substance P release. J Neurosci 25:3651-660 CrossRef
  11. Mabuchi T, Matsumura S, Okuda-Ashitaka E, Kitano T, Kojima H, Nagano T, Minami T, Ito S (2003) Attenuation of neuropatic pain by the nociception/orphanin FQ antagonist JTC-801 is mediated by inhibition of nitric oxide production. Eur J Neurosci 17(7):1384-392 CrossRef
  12. Moriyama K, Liu J, Jang Y, Chae YJ, Wang Y, Mitchell J, Grond S, Han X, Xing Y, Xie GX, Pierce Palmer P (2009) Receptor mediation and nociceptin inhibition of bradykinin-induced plasma extravasation in the knee joint of the rat. Inflamm Res 58(12):873-80. doi:10.1007/s00011-009-0058-y CrossRef
  13. Nicholson JR, Paterson SJ, Menzies JR, Corbett AD, McKnight AT (1998) Pharmacological studies on the “orphan-opioid receptor in central and peripheral sites. Can J Physiol Pharmacol 76(3):304-13 CrossRef
  14. Sehgal N, Smith HS, Manchikanti L (2011) Peripherally acting opioids and clinical implications for pain control. Pain Physician 14:249-58
  15. Serrano-Gomez A, Thompson JP, Lambert D (2011) Nociceptin/orphanin FQ in inflammation and sepsis. Br J Anaesth 106:6-2 CrossRef
  16. Spadaro A, Ajello A, Luigiano C, Morace C, Resta ML, Berlinghieri G, Campo S, Scisca C, Alibrandi A, D’Arrigo G, Alessi N, Ferrau O, Freni MA (2006) Low utility of plasma nociception/orphanin FQ in the diagnosis of hepatocellular carcinoma. World J Gastroenterol 12(29):4716-720
  17. Stamer UM, Book M, Comos C, Zhang L, Nauck F, Stuber F (2011) Expression of the nociception precursor and nociception receptor is modulated in cancer and septic patients. Br J Anaest 106(4):566-72 CrossRef
  18. Stein C, Küchler S (2012) Non-analgesic effects of opioids: peripheral opioid effects on inflammation and wound healing. Curr Pharm Des 18(37):6053-069 CrossRef
  19. Tamai H, Sawamura S, Takeda K, Orili R, Hanaoka K (2005) Anti-allodynic and anti-hyperalgesic effects of nociception receptor antagonist, JTC-801, in rats after spinal nerve injury and inflammation. Eur J Pharmacol 510(3):223-28 CrossRef
  20. Tekes K, Hantos M, Bizderi B, Gyenge M, Kecskemeti V, Huszti Z (2006) Nociceptin-induced histamine release in the brain: competition with compound 48/80 and SP-induced amine secretion. Inflamm Res 55(Supl.1):S30-1
  21. Yaksh TL (1988) Substance P release from knee joint afferent terminals: modulation by opioids. Brain Res 458(2):319-24 CrossRef
  22. Zamfirova R, Tzvetanova E, Aleksandrova A, Petrov L, Mateeva P, Pavlova A, Kirkova M, Todorov S (2009) In vivo effects of N/OFQ(1-13)NH2 and its structural analogue [Orn9] N/OFQ(1-13)NH2 of carrageenan-induced inflammation: rat-paw oedema and antioxidant status. Central Eur J Biol 4(2):170-78 CrossRef
  23. Zamfirova R, Pavlov N, Todorov P, Mateeva P, Martinez J, Calmès M, Naydenova E (2013) Synthesis and changes in affinity for NOP and opioid receptors of novel hexapeptides containing β2-tryptophan analogues. Bioorg Med Chem Lett 23:4052-055 CrossRef
  24. Zeilhofer HU, Calo G (2003) Nociceptin/Orphanin FQ and its receptor-potential targets for pain therapy? J Pharmacol Exp Ther 306(2):423-29 CrossRef
  
• 作者单位：R. N. Zamfirova (1)
  P. I. Mateeva (1)
  N. D. Pavlov (2)
  E. D. Naydenova (2)
  
  1. Institute of Neurobiology, Bulgarian Academy of Sciences, 23 Acad. G. Bonchev str., 1113, Sofia, Bulgaria
  2. Department of Organic Chemistry, University of Chemical Technologies and Metallurgy, Sofia, Bulgaria
  
• ISSN：1573-3904

文摘

Following the discovery of the N/OFQ/NOP system and its modulatory role in physiological and pathophysiological processes, intensive study has started to find selective NOP ligands with hypothetic therapeutic potential. Among the agonists, a hexapeptide Ac-RYYRWK-NH2 has been identified. It expresses high NOP receptor affinity and selectivity. Its molecule was used as a template, in which Tyr5 was substituted by original β2-tryptophan analogue (S)-2-(1-methyl-1H-indol-3-yl)propionic residue (compound HP3) The new compound activates both NOP and opioid receptors. Having in mind that classical opioids, as well as nociceptin, are involved in modulating pain and inflammation, we examined the anti-inflammatory effect of newly-synthesized peptide HP3 on carrageenan-induced peripheral inflammation, and compared it with that of indomethacin (3?mg/kg). It was found that HP3 in dose 40?μg/kg exerts weaker anti-inflammatory action in the first 180?min of the experiment, but is equally effective with indomethacin 3?mg/kg at the end of the observation. The HP3 effect is due mainly of the activation of opioid receptors.